SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2026
Old and emerging therapies for childhood interstitial lung disease (chILD): a systematic review.
Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Regenerative strategies for surfactant deficiency in neonatal and pediatric lung disease: the role of mesenchymal stem cells and their extracellular vesicles.Frontiers in cell and developmental biology · 2026Review
- SAVI: molecular mechanisms, clinical spectrum and precision medicine approaches beyond type-I IFN.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood interstitial lung disease (chILD) is a heterogeneous group of rare lung diseases that comprises more than 200 entities. The diagnostic process for chILD might require multiple investigations, which often include a combination of clinical assessments, imaging studies, genetic testing and invasive procedures. Given the prolonged diagnostic timeline, supportive treatments are typically initiated followed by more targeted therapies generally postponed until the underlying cause of the disease is identified. This systematic review aims to describe the current knowledge regarding different treatment strategies for chILD and critically appraise, compare and qualitatively summarise the current evidence on old and emerging therapies for chILD. Of the 5775 publications returned from the initial search, 100 studies met the inclusion criteria, of which 50% were reviews or task force reports from several scientific societies, 41% case reports or case series, 5% randomised controlled trials and 4% preclinical studies on emerging therapies. In order to provide a clearer description of the data analysed, we describe available therapeutic options for chILD in general, organised by treatment type, and then we report treatments categorised by specific pathology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.